Clinical Trial Update: To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating CKD-519 in combination with HMG-CoA reductase inhibitors for dyslipidemias has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• CKD-519

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Dyslipidemias | Phase 2 | Status: COMPLETED